Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group

• Published in: British journal of ophthalmology Vol. 102; no. 4; pp. 455 - 459
• Main Authors: Chhablani, Jay, Paulose, Remya Mareen, Lasave, Andres F, Wu, Lihteh, Carpentier, Cristian, Maia, Mauricio, Lujan, Silvio, Rojas, Sergio, Serrano, Martin, Berrocal, Maria H, Arevalo, J Fernando
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.04.2018
• Subjects: Adult; Age; Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Bevacizumab - administration & dosage; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - etiology; Choroidal Neovascularization - physiopathology; Collaboration; Female; Humans; Immunotherapy; Macular degeneration; Male; Medical imaging; Medical prognosis; Middle Aged; Monoclonal antibodies; Myopia - complications; Ophthalmology; Patients; Retrospective Studies; Statistical analysis; Visual Acuity - physiology; United States > US; California; anti-VEGF; bevacizumab; myopia; choroidal neovascularization

PurposeTo report the long-term anatomical and visual outcomes of intravitreal bevacizumab (IVB) monotherapy in naive choroidal neovascularisation (CNV) caused by myopia.MethodsRetrospective analysis of naive CNV secondary to myopia that underwent antivascular endothelial growth factor monotherapy wa...